Compare JMIA & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JMIA | SLBT |
|---|---|---|
| Founded | 2012 | N/A |
| Country | Germany | Taiwan |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 865.9M | 846.7M |
| IPO Year | 2018 | 2025 |
| Metric | JMIA | SLBT |
|---|---|---|
| Price | $6.11 | $1.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $12.13 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 70.5K |
| Earning Date | 11-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.10 | N/A |
| Revenue Next Year | $24.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.59 | $1.42 |
| 52 Week High | $14.72 | $6.25 |
| Indicator | JMIA | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 36.83 | 39.30 |
| Support Level | $5.70 | $1.42 |
| Resistance Level | $6.29 | $1.98 |
| Average True Range (ATR) | 0.26 | 0.14 |
| MACD | -0.11 | 0.04 |
| Stochastic Oscillator | 32.78 | 27.72 |
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace that connects sellers with consumers. The logistics services of the company enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. The company generates revenue from first-party sales, third-party sales, marketing and advertising, and the provision of other services. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.